


Anti-microbial susceptibility testing (AST) and bacteria detection assisting patients and antibiotics.



- Antibiotic resistance causes over 700,000 deaths annually. By 2050, it is projected to cause over 10,000,000 annually^{1,2}.
- Phenotypic AST yields precise targeted treatments, but current methods take days, leading to late results and limited use.
- Our prototypes provide **phenotypic AST results in 4-6 hours** allowing fast, targeted treatments to heal patients.
- Targeted treatments also extend the service life of antibiotics by quickly eliminating microbes and mitigating AMR risk.



- AST is a \$3B global market with a 6% CAGR. Consumables are 73% of those expenditures.
- Detection is a \$4B global market with a similar rate for consumables.
- By 2027, detection and AST are projected to be a combined \$13B annual global market.
- By contrast, only 13 new antibiotics are in Phase 3 trials.³ Health experts insist we increase AST to enhance antibiotic stewardship.¹
- Acenxion's core development team previously developed and marketed numerous devices. We have the skills and network to succeed.
- Our prototypes are scalable and seamlessly integrate into current laboratory workflows.
- We seek participants in post-money SAFE Agreements to complement a multi-million dollar NIH grant.

A diagnostic partner for patients and antibiotics

1. 2019 CDC report, "Antibiotic Resistance Threats in the United States."
2. 2019 Interagency Coordination Group on Antimicrobial Resistance report, "No Time to Wait: Securing the future from drug-resistant infections."
3. 2020 Pew Charitable Trust report, "Tracking the Global Pipeline of Antibiotics in Development, April 2020"

Company profile

Contact
Dr. Roy Swiger, CEO
roy@acxbio.com
321-749-0523